SVRA
Savara Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.37
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 20.7M | 245.0K | 78.0M | 44.3M | 27.9M |
| Gross Profit | (20.7M) | (245.0K) | (78.0M) | (44.3M) | (27.9M) |
| Operating Expenses | |||||
| R&D Expense | 86.8M | 81.4M | 78.0M | 44.3M | 27.9M |
| SG&A Expense | 56.7M | 42.1M | 25.0M | 15.7M | 10.9M |
| General & Admin Expense | 56.7M | 42.1M | 25.0M | 15.7M | 10.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (20.5M) | 87.0K | (77.9M) | (44.2M) | (27.8M) |
| Total Operating Expenses | 122.9M | 123.3M | 25.2M | 15.7M | 11.0M |
| Cost and Expenses | 143.6M | 123.5M | 103.2M | 60.0M | 38.8M |
| Operating Income (EBIT) | (143.6M) | (123.5M) | (103.2M) | (60.0M) | (38.8M) |
| Non-Operating | |||||
| Interest Income | 3.6M | 4.2M | 6.5M | 4.4M | 88.00 |
| Interest Expense | — | — | — | — | 88.0K |
| Net Interest Income | 3.6M | 4.2M | 6.5M | 4.4M | (87.9K) |
| Other Non-Op Income/Expense | 4.3M | 4.7M | 7.3M | 5.3M | 689.0K |
| Non-Operating Income (excl Interest) | (4.3M) | (4.7M) | (797.0K) | (797.0K) | (796.0K) |
| EBT (Pre-Tax Income) | (139.3M) | (118.8M) | (95.9M) | (54.7M) | (38.1M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (139.3M) | (118.8M) | (95.9M) | (54.7M) | (38.1M) |
| Earnings from Cont. Ops | (139.3M) | (118.8M) | (95.9M) | (54.7M) | (38.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (139.3M) | (118.8M) | (95.9M) | (54.7M) | (38.1M) |
| Per Share | |||||
| Basic EPS | ($0.58) | ($0.53) | ($0.48) | ($0.33) | ($0.25) |
| Diluted EPS | ($0.58) | ($0.53) | ($0.48) | ($0.33) | ($0.25) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 253.6M | 222.4M | 198.2M | 165.2M | 152.8M |
| Diluted Shares Outstanding | 253.6M | 222.4M | 198.2M | 165.2M | 152.8M |
| Profitability Metrics | |||||
| EBITDA | (139.1M) | (118.6M) | (102.3M) | (59.1M) | (38.0M) |
| D&A | 209.0K | 245.0K | 130.0K | 77.0K | 31.0K |
| EBIT | (139.3M) | (118.8M) | (102.4M) | (59.2M) | (38.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026